

Comparison of Two Assays for Molecular Determination of Rifampin Resistance in Clinical Samples from Patients with Buruli Ulcer Disease

Moritz Jansson,^a Marcus Beissner,^a Richard Odame Phillips,^b Kossi Badziklou,^c Ebekalisai Piten,^d Issaka Maman,^c Fred Stephen Sarfo,^b Kristina Lydia Huber,^a Agata Rhomberg,^a Dominik Symank,^a Magdalena Wagner,^a Franz Wiedemann,^e Jörg Nitschke,^{a,e} Abiba Banla Kere,^c Karl-Heinz Herbinger,^a Ohene Adjei,^b Thomas Löscher,^a Gisela Bretzel^a

Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians-University, Munich, Germany^a; Komfo Anokye Teaching Hospital (KATH), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana^b; Institut National d'Hygiène (INH), Ministère de la Santé, Lomé, Togo^c; Centre Hospitalier Régional Maritime (CHR-Maritime), Tsévié, Togo^d; German Leprosy and Tuberculosis Relief Association (GLRA), Togo Office (GLRAT), Lomé, Togo^e

This study evaluates a novel assay for detecting rifampin resistance in clinical *Mycobacterium ulcerans* isolates. Although highly susceptible for PCR inhibitors in 50% of the samples tested, the assay was 100% *M. ulcerans* specific and yielded >98% analyzable sequences with a lower limit of detection of 100 to 200 copies of the target sequence.

Buruli ulcer disease (BUD), caused by *Mycobacterium ulcerans*, involves the skin, subcutaneous fatty tissue, and bones and predominantly affects children <15 years of age. If left untreated, contractures may cause severe functional limitation. Standardized antimycobacterial treatment consists of rifampin (RMP) and streptomycin administered for 8 weeks. An oral regimen combining RMP and clarithromycin is currently under clinical evaluation (1–3). Notwithstanding the efficiency of chemotherapy, treatment failures and various types of secondary lesions have been reported, suggesting the need for customized clinical management strategies (4–6).

Tuberculosis and leprosy studies have shown that RMP treatment is prone to the development of drug resistance due to missense mutations within the RMP resistance-determining region (RRDR) of the mycobacterial *rpoB* gene (7, 8). RRDR mutations in *M. ulcerans* have been described in a mouse model (9); data on drug resistance among clinical isolates, however, are scarce. A pilot study on molecular drug resistance testing conducted by our group from 2004 through 2007 in Ghana revealed a low level (0.9%) of RMP resistance. However, the overall test efficiency of the assay applied in the pilot study (referred to here as assay A) was low (35%) (10). Therefore, the aim of this study was to develop an improved sequencing assay (referred to here as assay B).

The study was approved by the National Togolese Ethics Committee (14/2010/CRBS) and the Ghanaian Kwame Nkrumah University of Science and Technology Ethics Committee (CHRPE/91/10).

The primers MuB-F and MuB-R were designed to amplify a 606-bp region encompassing the RRDR by alignment of (myco)bacterial *rpoB* genes as retrieved from GenBank (PubMed, NCBI) using DNASIS Max (MiraiBio, San Francisco, CA) (see Table S1 in the supplemental material). MuB-F specifically binds a polymorphic region of the mycobacterial *rpoB* gene (11); the sequencing primer Bseek-F binds downstream of primer MuB-F (Table 1). Amplification was conducted using the *Thermococcus kodakaraensis*-derived KOD Hot Start polymerase (Merck, Darmstadt, Germany) followed by performing agarose gel electrophoresis, purification of PCR products, cycle sequencing, and sequence analysis, as previously described (10) (Table 1; see also PCR Protocol S2 and S3 in the supplemental material).

PCR standards were generated by exact quantification of

whole-genome DNA from two *M. ulcerans* cultures from Ghana by IS2404 quantitative real-time PCR (12, 13). The limits of detection for the two assays were determined by testing 10-fold serial dilutions of PCR standards. The analytical sensitivity of assay B was 10 times higher than that of assay A (100 to 200 and 1,000 to 2,000 copies of the *rpoB* gene, respectively).

The specificity of assay B was assessed with DNA extracts of 18 closely related human-pathogenic mycobacterial species and five bacterial species frequently colonizing human skin (12, 14–16) (Table 2). Besides *M. ulcerans*, only *M. marinum* was amplified. As *rpoB* wild-type sequences of these two species can be differentiated in two nucleotides by sequencing, assay B was considered *M. ulcerans* specific.

To determine the performances of the two assays on clinical specimens, 133 whole-genome extracts from IS2404-positive samples collected before the onset of treatment (swab samples, $n = 63$; fine-needle aspirates [FNA], $n = 40$; 3-mm punch biopsy specimens, $n = 30$) from 91 BUD patients from Togo (17, 18) were assessed. P values of <0.05 were considered significant.

Due to initial *rpoB* PCR inhibition, significantly more DNA extracts had to be diluted when subjected to assay B (54.1%, 72/133) than when subjected to assay A (7.5%, 10/133) ($P < 0.01$). With a P value of 0.39, the overall *rpoB* PCR positivity rate (i.e., the proportion of positive *rpoB* PCR results among all samples tested) was not significantly different in assay A (56.4%, 75/133) and assay B (51.1%, 68/133). However, the *rpoB* PCR positivity rate of swab samples was significantly higher in assay A (50.8%, 32/63) than in

Received 17 November 2013 Returned for modification 24 December 2013

Accepted 22 January 2014

Published ahead of print 29 January 2014

Editor: G. A. Land

Address correspondence to Moritz Jansson, moritz_jan@hotmail.de, or Marcus Beissner, beissner@lrz.uni-muenchen.de.

M.J. and M.B. contributed equally to this work.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JCM.03119-13>.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JCM.03119-13

TABLE 1 Primer sequences and nucleotide positions of *rpoB* PCR and sequencing primers^a

Assay	Primer ^b	Sequence (5' to 3') ^c	Nucleotide position ^d	Amplicon size, bp ^e
A ^f	MF	CGA CCA CTT CGG CAA CCG	785041–785058	351
	MR	TCG ATC GGG CAC ATC CCG	785374–785391	
B ^g	MuB-F	CAT CAC CAG CTC GAC GCT	784912–784929	606
	MuB-R	TGG ATC TCG TCG GAA ACG	785500–785517	
	Bseek-F	AAT ACC TGG TCC GCT TGC	784959–784976	

^a Shown are the primer sequences, nucleotide positions within the *M. ulcerans* genome, and corresponding amplicon sizes. The *rpoB* gene encodes the beta subunit of (myco)bacterial RNA polymerases. Significant sequence concordances of primers with human or other (myco)bacterial DNA were excluded by Primer BLAST (PubMed, NCBI).

^b F, forward primer; R, reverse primer. Primers MF and MR were used in assay A for the amplification of a 351-bp fragment of the *M. ulcerans rpoB* gene (including the RRDR) encompassing the region sequenced by primer MF. Primers MuB-F and MuB-R were used in assay B for the amplification of a 606-bp fragment of the *M. ulcerans rpoB* gene (including the RRDR) encompassing the region sequenced by primer Bseek-F.

^c Primer sequence from the 5' to the 3' end.

^d Nucleotide positions are provided for the respective amplicon in *M. ulcerans* strain Agy99 (GenBank accession no. CP000325 [PubMed, NCBI]).

^e Amplicon sizes for *rpoB* PCR of assay A or B, respectively.

^f For assay A, final concentrations of PCR reagents per 20- μ l reaction: 0.5 μ M each primer (TIB-Molbiol, Berlin, Germany); 2.5 mM MgCl₂, 0.8 mM deoxynucleoside triphosphates (dNTPs), 0.05 U/ μ l AmpliTaq Gold DNA polymerase, 1 \times PCR buffer II (Applied Biosystems, Foster City, CA); template DNA, 2 μ l; run protocol, 95°C for 5 min, 37 cycles at 95°C for 15 s, 56°C for 15 s, and 72°C for 30 s, and final extension at 72°C for 5 min.

^g For assay B, final concentrations of PCR reagents per 20- μ l reaction: 0.3 μ M each primer (TIB-Molbiol); 1.5 mM MgSO₄, 0.8 mM dNTPs, 0.02 U/ μ l KOD Hot Start polymerase, 1 \times PCR buffer for KOD (Merck, Darmstadt, Germany); template DNA, 2 μ l; run protocol, 95°C for 2 min and 39 cycles at 95°C for 20 s, 63°C for 10 s, and 70°C for 15 s.

assay B (30.2%, 19/63) ($P = 0.02$). Among all of the samples with a positive *rpoB* PCR result in both assays, the proportion of samples yielding a definite sequencing result (overall *rpoB* sequencing positivity rate) was significantly higher for assay B (98.0%, 48/49)

TABLE 2 Specificity of assay B^a

Bacterial species	Source ^b	Isolate origin	Result ^c
<i>Mycobacterium abscessus</i>	NRZ	Human ^d	–
<i>Mycobacterium africanum</i>	NRZ	Human ^d	–
<i>Mycobacterium avium</i>	NRZ	Human ^d	–
<i>Mycobacterium bovis</i>	NRZ	Cattle ^d	–
<i>Mycobacterium chelonae</i>	NRZ	Human ^d	–
<i>Mycobacterium fortuitum</i>	NRZ	Human ^e	–
<i>Mycobacterium gordonae</i>	NRZ	Human ^e	–
<i>Mycobacterium gordonae</i>	DITM	Human ^e	–
<i>Mycobacterium kansasii</i>	NRZ	Human ^d	–
<i>Mycobacterium leprae</i>	DITM	Human ^d	–
<i>Mycobacterium malmoense</i>	NRZ	Human ^e	–
<i>Mycobacterium marinum</i>	NRZ	Human ^d	+
<i>Mycobacterium microti</i>	NRZ	Mouse ^d	–
<i>Mycobacterium scrofulaceum</i>	NRZ	Human ^d	–
<i>Mycobacterium smegmatis</i>	NRZ	Human ^d	–
<i>Mycobacterium szulgai</i>	NRZ	Human ^d	–
<i>Mycobacterium tuberculosis</i>	NRZ	Human ^d	–
<i>Mycobacterium ulcerans</i>	DITM	Human ^d	+
<i>Mycobacterium xenopi</i>	NRZ	Human ^e	–
<i>Escherichia coli</i>	MVP	Human ^e	–
<i>Propionibacterium acnes</i>	MVP	Human ^d	–
<i>Staphylococcus aureus</i>	MVP	Human ^e	–
<i>Staphylococcus epidermidis</i>	MVP	Human ^e	–
<i>Streptococcus pyogenes</i>	MVP	Human ^d	–

^a Shown are (myco)bacterial species commonly contaminating human skin and the results of the specificity testing of sequencing assay B.

^b DNA extracts that were not available at the Department of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-University, Munich, Germany (DITM) were provided by the National Reference Center for Mycobacteria, Borstel, Germany (NRZ), and the Max von Pettenkofer-Institut, Ludwig-Maximilians-University, Munich, Germany (MVP).

^c Results of DNA extracts subjected to assay B: +, positive PCR result; –, negative PCR result.

^d The primary patient isolates were considered pathogenic bacteria.

^e The primary patient isolates were considered commensals/contaminants of clinical samples.

than for assay A (85.7%, 42/49) ($P = 0.03$). Among all the samples tested, the proportion of samples yielding a definite *rpoB* sequencing result (overall test efficiency) was 39.8% (53/133) for assay A and 48.9% (65/133) for assay B ($P = 0.14$). Following stratification of the overall test efficiencies into different sample types, the test efficiency for FNA samples was significantly higher in assay B (70.0%, 28/40) than in assay A (35.0%, 14/40) ($P < 0.01$) (Table 3).

The *Mycobacterium* genus-specific primers applied in assay A resulted in 30.7% (23/75) coamplification of DNA from other bacterial species (e.g., *Corynebacterium* species), resulting in non-analyzable mixed *rpoB* sequences in these cases. In contrast, assay B did not detect any species other than *M. ulcerans* strain Agy99 (data not shown).

Furthermore, 12 IS2404 PCR-confirmed whole-genome extracts from the pretreatment samples of 10 BUD patients from Ghana which had yielded contaminated sequences ($n = 9$) or no sequencing results ($n = 3$) in assay A (10) were reexamined with assay B. Out of these, 11 (91.7%) rendered definite *M. ulcerans rpoB* wild-type sequences, and one sample remained negative in assay B.

The current level of RMP resistance among clinical *M. ulcerans* isolates in countries where BUD is endemic is unknown. Although there is no evidence for, and therefore no general concern about, person-to-person transmission of drug-resistant *M. ulcerans* strains, individual treatment outcomes of BUD patients may be compromised by drug resistance evolving under chemotherapy. Slow-healing lesions related to drug resistance may negatively influence the manifestation of disabilities; nonhealers and recurrences caused by resistant strains may benefit from timely surgical intervention in default of alternative antimycobacterial drugs. Therefore, rapid molecular assays for the detection of drug resistance constitute valuable tools for supporting individual clinical management decisions and prerequisites for new drug trials.

Although the overall *rpoB* PCR positivity rates and overall test efficiencies did not differ significantly in the two assays we compared, 20% more *rpoB* amplicons were generated from swab samples in assay A. However, due to the high specificity of sequencing assay B, out of those swab samples with a positive *rpoB* PCR in both assays, 100% yielded analyzable sequences in assay B, in con-

TABLE 3 Comparison of the results from clinical samples of Togolese BUD patients subjected to assays A^a and B^{b,c}

Test, parameter, and sample collection type	% (no. of samples with a positive result/no. of samples tested) (95% confidence interval)			
	PCR A	PCR B	PCR A and PCR B (concordance rate) ^d	McNemar's P ^e
<i>rpoB</i> PCR				
Positivity rate ^f				
All	56.4 (75/133) (48.0–64.8)	51.1 (68/133) (42.6–59.6)	66.2 (88/133) (58.1–74.2)	0.39
Swabs	50.8 (32/63) (38.4–63.1)	30.2 (19/63) (18.8–41.5)	57.1 (36/63) (44.9–69.4)	0.02 ^g
Punch biopsy	73.3 (22/30) (57.5–89.2)	66.7 (20/30) (49.8–83.5)	86.7 (26/30) (74.5–98.8)	0.58
FNA	52.5 (21/40) (37.0–68.0)	72.5 (29/40) (58.7–86.3)	65.0 (26/40) (50.2–79.8)	0.06
Initial inhibition ^h				
All	07.5 (10/133) (03.0–12.0)	54.1 (72/133) (45.7–62.6)	48.9 (65/133) (40.4–57.4)	<0.01 ^g
Swabs	09.5 (6/63) (02.3–16.8)	65.1 (41/63) (53.3–76.9)	41.3 (26/63) (29.1–53.4)	<0.01 ^g
Punch biopsy	06.7 (2/30) (00.0–15.6)	30.0 (9/30) (13.6–46.4)	76.7 (23/30) (61.5–91.8)	0.02 ^g
FNA	05.0 (2/40) (00.0–11.8)	55.0 (22/40) (39.6–70.4)	40.0 (16/40) (24.8–55.2)	<0.01 ^g
<i>rpoB</i> -Sequencing				
Positivity rate ⁱ				
All	85.7 (42/49) (75.9–95.5)	98.0 (48/49) (94.0–100)	87.8 (43/49) (78.6–96.9)	0.03 ^{g,j}
Swabs	75.0 (9/12) (50.5–99.5)	100 (12/12) (NA ^k)	75.0 (9/12) (50.5–99.5)	0.07 ^j
Punch biopsy	100 (19/19) (NA ^k)	100 (19/19) (NA ^k)	100 (19/19) (NA ^k)	NA ^k
FNA	77.8 (14/18) (58.6–97.0)	94.4 (17/18) (83.9–100)	77.8 (14/18) (58.6–97.0)	0.15 ^j
Efficiency ^l				
All	39.8 (53/133) (31.5–48.2)	48.9 (65/133) (40.4–57.4)	74.4 (99/133) (67.0–81.8)	0.14
Swabs	28.6 (18/63) (17.4–39.7)	27.0 (17/63) (16.0–37.9)	73.0 (46/63) (62.1–84.0)	0.84
Punch biopsy	70.0 (21/30) (53.6–86.4)	66.7 (20/30) (49.8–83.5)	90.0 (27/30) (79.3–100)	0.78
FNA	35.0 (14/40) (20.2–49.8)	70.0 (28/40) (55.8–84.2)	65.0 (26/40) (50.2–79.8)	<0.01 ^g

^a Assay A as applied in the pilot study.

^b The newly developed assay B.

^c Shown are PCR and sequencing results of all clinical samples subjected to assays A and B.

^d Proportion of samples with concordant results in assays A and B out of all samples tested by both assays.

^e P value of McNemar chi-square test for matched pairs of samples with categorical test results.

^f Overall *rpoB* PCR positivity rate: the proportion of positive *rpoB* PCR results among all samples tested (assay A or B, respectively).

^g P values of <0.05 were considered significant.

^h Proportion of samples which led to PCR inhibition if tested undiluted out of all samples tested by PCR in assay A or B, respectively.

ⁱ Overall *rpoB*-sequencing positivity rate: proportion of samples yielding a definite sequencing result among all samples with a positive *rpoB* PCR result in both assays.

^j Fisher's exact test (at least one cell, $n < 5$).

^k NA, not applicable.

^l Overall test efficiency: the proportion of samples yielding a definite sequencing result (assay A and/or B) among all samples tested.

trast to 75% in assay A. In general, assay A resulted in 30% mixed sequences, while assay B yielded a significantly higher proportion of definite sequencing results with 98% analyzable sequences. However, the overall susceptibility of assay B to the presence of PCR inhibitors was considerable, as 50% of all clinical samples had to be diluted, compared to <10% of them in assay A. In turn, dilution leads to decreased *M. ulcerans* DNA yields, certainly affecting the *rpoB* PCR positivity rate of assay B. Furthermore, for FNA samples, the overall test efficiency was significantly higher in assay B (70%), suggesting FNAs as the most appropriate sample type for molecular drug resistance testing, which is compatible with current WHO recommendations for sample collection (19).

In conclusion, assay B constitutes a sensitive and 100% *M. ulcerans*-specific molecular tool for determining rifampin resistance with the highest efficiency in FNA samples. In combination with a recently described 16S rRNA-based viability assay (12), molecular drug resistance testing would also allow a reliable differentiation of individuals harboring viable drug-resistant organisms opposed to mycobacterial DNA residues detectable in secondary lesions (4). Furthermore, novel real-time PCR high-resolution melt analysis assays without allele-specific primers or probes may constitute a promising tool for screening clinical isolates in future studies (20).

ACKNOWLEDGMENTS

This work was supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement 241500.

We thank Kerstin Helfrich and Carolin Mengele (DITM) for laboratory assistance, Florian Battke (Dr. Battke Scientia GmbH) for technical advice, Sabine Rüscher-Gerdes, Elvira Richter (Research Center Borstel), and Soeren Schubert (Max von Pettenkofer-Institut, LMU) for providing (myco)bacterial strains, and Basile Kobara ("Programme National de Lutte contre l'Ulcère de Buruli, Lèpre et Pian") for excellent collaboration.

This article contains parts of the doctoral thesis of Moritz Jansson.

REFERENCES

- Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundoté A, Cottin J, Ladikpo T, Ruf T, Ji B. 2011. Oral treatment for *Mycobacterium ulcerans* infection: results from a pilot study in Benin. Clin. Infect. Dis. 52:94–96. <http://dx.doi.org/10.1093/cid/ciq072>.
- Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS. 2010. Pharmacokinetics of rifampin and clarithromycin in patients treated for *Mycobacterium ulcerans* infection. Antimicrob. Agents Chemother. 54:3878–3883. <http://dx.doi.org/10.1128/AAC.00099-10>.
- Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. 2010. Antimicrobial treatment for early, limited *Mycobacterium ulcerans* infection: a randomised controlled trial. Lancet 375:664–672. [http://dx.doi.org/10.1016/S0140-6736\(09\)61962-0](http://dx.doi.org/10.1016/S0140-6736(09)61962-0).

4. Beissner M, Piten E, Maman I, Symank D, Jansson M, Nitschke J, Amekuse K, Kobara B, Wiedemann F, Hoffmann H, Diefenhardt A, Badziklou K, Banla Kere A, Löscher T, Bretzel G. 2012. Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy—a case report from Togo. *PLoS Negl. Trop. Dis.* 6:e1747. <http://dx.doi.org/10.1371/journal.pntd.0001747>.
5. Ruf MT, Chauty A, Adeye A, Ardant MF, Kousseuou H, Johnson RC, Pluschke G. 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? *PLoS Negl. Trop. Dis.* 5:e1252. <http://dx.doi.org/10.1371/journal.pntd.0001252>.
6. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, Hosking P, Johnson PD. 2011. Spontaneous clearance of *Mycobacterium ulcerans* in a case of Buruli ulcer. *PLoS Negl. Trop. Dis.* 5:e1290. <http://dx.doi.org/10.1371/journal.pntd.0001290>.
7. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. 1993. Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* 341:647–650. [http://dx.doi.org/10.1016/0140-6736\(93\)90417-F](http://dx.doi.org/10.1016/0140-6736(93)90417-F).
8. Honoré N, Cole ST. 1993. Molecular basis of rifampin resistance in *Mycobacterium leprae*. *Antimicrob. Agents Chemother.* 37:414–418. <http://dx.doi.org/10.1128/AAC.37.3.414>.
9. Marsollier L, Honoré N, Legras P, Manceau AL, Kouakou H, Carbonnelle B, Cole ST. 2003. Isolation of three *Mycobacterium ulcerans* strains resistant to rifampin after experimental chemotherapy of mice. *Antimicrob. Agents Chemother.* 47:1228–1232. <http://dx.doi.org/10.1128/AAC.47.4.1228-1232.2003>.
10. Beissner M, Awua-Boateng NY, Thompson W, Nienhuis WA, Klutse E, Agbenorku P, Nitschke J, Herbinger KH, Siegmund V, Fleischmann E, Adjei O, Fleischer B, van der Werf TS, Löscher T, Bretzel G. 2010. A genotypic approach for detection, identification, and characterization of drug resistance in *Mycobacterium ulcerans* in clinical samples and isolates from Ghana. *Am. J. Trop. Med. Hyg.* 83:1059–1065. <http://dx.doi.org/10.4269/ajtmh.2010.10-0263>.
11. Lee H, Bang HE, Bai GH, Cho SN. 2003. Novel polymorphic region of the *rpoB*-gene containing *Mycobacterium* species-specific sequences and its use in identification of *Mycobacteria*. *J. Clin. Microbiol.* 41:2213–2218. <http://dx.doi.org/10.1128/JCM.41.5.2213-2218.2003>.
12. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng NY, Sarfo FS, Jansson M, Huber KL, Herbinger KH, Battke F, Löscher T, Adjei O, Bretzel G. 2012. Detection of viable *Mycobacterium ulcerans* in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. *PLoS Negl. Trop. Dis.* 6:e1756. <http://dx.doi.org/10.1371/journal.pntd.0001756>.
13. Fyfe JA, Lavender CJ, Johnson PD, Globan M, Sievers A, Azuolas J, Stinear TP. 2007. Development and application of two multiplex real-time PCR assays for the detection of *Mycobacterium ulcerans* in clinical and environmental samples. *Appl. Environ. Microbiol.* 73:4733–4740. <http://dx.doi.org/10.1128/AEM.02971-06>.
14. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, Kim EC, Cha CY, Kook YH. 1999. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (*rpoB*). *J. Clin. Microbiol.* 37:1714–1720.
15. Kim BJ, Lee KH, Park BN, Kim SJ, Bai GH, Kim SJ, Kook YH. 2001. Differentiation of mycobacterial species by PCR-restriction analysis of DNA (342 base pairs) of the RNA polymerase gene (*rpoB*). *J. Clin. Microbiol.* 39:2102–2109. <http://dx.doi.org/10.1128/JCM.39.6.2102-2109.2001>.
16. Gingeras TR, Ghandour G, Wang E, Berno A, Small PM, Drobniewski F, Alland D, Desmond E, Holodniy M, Drenkow J. 1998. Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic *Mycobacterium* DNA arrays. *Genome Res.* 8:435–448.
17. Bretzel G, Huber KL, Kobara B, Beissner M, Piten E, Herbinger KH, Wiedemann FX, Amekuse K, Banla Kere A, Helfrich K, Fleischmann E, Löscher T, Diefenhardt A, Nitschke J. 2011. Laboratory confirmation of Buruli ulcer disease in Togo. *PLoS Negl. Trop. Dis.* 5:e1228. <http://dx.doi.org/10.1371/journal.pntd.0001228>.
18. Beissner M, Huber KL, Badziklou K, Halatoko WA, Maman I, Vogel F, Bidjada B, Awoussi KS, Piten E, Helfrich K, Mengelle C, Nitschke J, Amekuse K, Wiedemann FX, Diefenhardt A, Kobara B, Herbinger KH, Banla Kere A, Prince-David M, Löscher T, Bretzel G. 2013. Implementation of a national reference laboratory for Buruli ulcer disease in Togo. *PLoS Negl. Trop. Dis.* 7:e2011. <http://dx.doi.org/10.1371/journal.pntd.0002011>.
19. World Health Organization 2010. Guidance on sampling techniques for laboratory-confirmation of *Mycobacterium ulcerans* infection (Buruli ulcer disease). World Health Organization, Geneva, Switzerland.
20. Li W, Matsuoka M, Kai M, Thapa P, Khadge S, Hagge DA, Brennan PJ, Vissa V. 2012. Real-time PCR and high-resolution melt analysis for rapid detection of *Mycobacterium leprae* drug resistance mutations and strain types. *J. Clin. Microbiol.* 50:742–753. <http://dx.doi.org/10.1128/JCM.05183-11>.